Evidence map›Paper›PMID 37788600›Full record

ReviewJournal of addiction medicine

Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl.

H Elizabeth Bird, Andrew S Huhn, Kelly E Dunn

Open access · greenAbstract readReview
In one paragraph

Review in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
26.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Guideline
  2. Effects of TPA023B, an α2/3/5GABAPsychopharmacology · 2026
    Article
  3. Review
  4. Clinical Use of Endotracheal Intubation Without Neuromuscular Blockade: The Current Stage of Knowledge.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  5. Article
  6. Beyond respiratory depression: acute and delayed pulmonary responses following aerosolized fentanyl exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Fentanyl blockade of KThe Journal of physiology · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

H Elizabeth BirdFrom the Johns Hopkins University School of Medicine, Baltimore, MD (HEB, ASH, KED).
Andrew S Huhn
Kelly E Dunn
Johns Hopkins University · US

Funding

Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
Evaluating Suvorexant for Sleep Disturbance in Opioid Use DisorderUH3DA048734 · NIDA · JOHNS HOPKINS UNIVERSITY · PI DUNN, KELLY E, HUHN, ANDREW S · 2021 to 2021
$3.6M
Assessing a Clinically-meaningful Opioid Withdrawal PhenotypeR01DA052937 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI DUNN, KELLY E · 2021 to 2025
$3.3M
NIDA NIH HHS R01 DA052937NIDA NIH HHS UH3 DA048734NIGMS NIH HHS T32 GM066691
6 · The paper itself

Abstract

objectivesThis narrative review summarizes literature on pharmaceutical fentanyl's absorption, distribution, metabolism, and excretion patterns to inform research on illicitly manufactured fentanyl (IMF).

resultsFentanyl is highly lipophilic, lending itself to rapid absorption by highly perfused tissues (including the brain) before redistributing from these tissues to muscle and fat. Fentanyl is eliminated primarily by metabolism and urinary excretion of metabolites (norfentanyl and other minor metabolites). Fentanyl has a long terminal elimination, with a documented secondary peaking phenomenon that can manifest as "fentanyl rebound." Clinical implications in overdose (respiratory depression, muscle rigidity, and "wooden chest syndrome") and opioid use disorder treatment (subjective effects, withdrawal, and buprenorphine-precipitated withdrawal) are discussed. The authors highlight research gaps derived from differences in medicinal fentanyl studies and IMF use patterns, including that medicinal fentanyl studies are largely conducted with persons who were opioid-naive, anesthetized, or had severe chronic pain and that IMF use is characterized by supratherapeutic doses and frequent and sustained administration patterns, as well as adulteration with other substances and/or fentanyl analogs.

conclusionsThis review reexamines information yielded from decades of medicinal fentanyl research and applies elements of the pharmacokinetic profile to persons with IMF exposure. In persons who use drugs, peripheral accumulation of fentanyl may be leading to prolonged exposure. More focused research on the pharmacology of fentanyl in persons using IMF is warranted.

Indexed as

Chronic PainDrug OverdoseAnalgesics, OpioidClinical RelevanceFentanylHumansAnalgesics, OpioidFentanyl

Identifiers

PMID37788600
PMCPMC10593981
OpenAlexW4376873082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.